Navigation Links
ORTHOCON® Names David J. Hart Vice President of Business Operations
Date:3/15/2012

IRVINGTON, N.Y., March 15, 2012 /PRNewswire/ -- ORTHOCON®, Inc., a privately-held surgical device company, today announced that David J. Hart has been appointed Vice President of Business Operations. Mr. Hart will be responsible for in-licensing and acquiring new products and technologies for development and distribution by ORTHOCON's R&D and commercial teams. 

Mr. Hart joins ORTHOCON from Alpine Capital Group, a leading family office investment fund where, as President and Chief Investment Officer, he was responsible for all private equity and indirect capital investments and healthcare research. Prior to Alpine Capital, David was Principal and Senior Research Analyst at Apelles Investment Management, a cross-capital healthcare investment fund focused on public and private investing in medical device, healthcare service, and healthcare information technology companies. Mr. Hart began his career in the merger and acquisition groups at Thomas Weisel and Partners and Duff and Phelps. He earned a MBA from Columbia University and a BA from Duke where he was a member of the varsity golf team.

"I am thrilled to have David on our senior leadership team," said John J. Pacifico, President and Chief Executive Officer of ORTHOCON. "Having known David for several years and watched him achieve tremendous professional success directly relevant to ORTHOCON's business plan, I know he is perfect for this role and I fully expect him to add significant value to ORTHOCON and to our shareholders."

"I've had the opportunity to watch ORTHOCON evolve over the last five years. John has built a dynamic organization with a robust R&D pipeline and a truly differentiated commercialization strategy," said David Hart. "I am excited to join the ORTHOCON team and look forward to helping John execute on his strategic vision for the company."

About ORTHOCON
Founded in 2005, ORTHOCON develops, acquires, manufactures, and markets surgical products. In 2011, ORTHOCON announced the commercial introduction of its first FDA cleared product, Hemasorb Resorbable Hemostatic Bone Putty, and the clearance of Hemasorb Apply, a proprietary applicator designed to deliver Hemasorb and other ORTHOCON products presently under development. Also in 2011, ORTHOCON announced a strategic partnership with Bezwada Biomedical which gave ORTHOCON worldwide rights to develop and market Bezwada's absorbable polyurethane technology for bone applications. 

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its state-of-the-art facility in Irvington, New York. For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORTHOCON®, Inc. Receives 510(k) Clearance to Market HEMASORB Apply™
2. ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®
3. ORTHOCON® Announces U.S. Market Launch of HEMASORB®
4. Zeus Healthcare Names Larry Havelis as CEO
5. RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation
6. InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development
7. SalesCongo Names Ken Kaisen CEO
8. UNT System Names Jacobson Founding Dean of College of Pharmacy
9. LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors
10. Premier Research Names Etienne Drouet Executive Director, Oncology Europe
11. Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):